FDA Proposes the Removal and Addition of Substances to Its 503A Bulks List

Article

The FDA has created a new proposed rule that adds 6 bulk drug substances to an existing list of substances that can be used in compounding. It has also proposed the removal of 4 other bulk drug substances from the list.

The FDA has created a new proposed rule that adds 6 bulk drug substances to an existing list of substances that can be used in compounding. It has also proposed the removal of 4 other bulk drug substances from the list.

The 6 new inclusions would be:

  • Brilliant Blue G, also known as Coomassie Brilliant Blue G-250, as a dye used in staining for visualization during ophthalmic procedures
  • Cantharidin (for topical use only) for the treatment of warts and molluscum contagiosum
  • Diphenylcyclopropenone (for topical use only) for the treatment of alopecia areata and nongenital warts
  • N-acetyl-D-glucosamine (for topical use only) for the treatment of hyperpigmentation and other skin conditions
  • Squaric acid dibutyl ester (for topical use only) for the treatment of alopecia areata and recalcitrant nongenital warts
  • Thymol iodide (for topical use only) for ulcerations and skin infections, as well as an intrapleural treatment for pleural effusions

The products that would be removed are:

  • Oxitriptan (evaluated as a treatment for depression and insomnia)
  • Piracetam (evaluated as a treatment for enhancing cognitive skills)
  • Silver protein mild (for use as an anti-infective agent for ophthalmic use)
  • Tranilast (for the treatment of allergic disorders, arthritis, dry eye syndrome, keloids, and hypertrophic scars.)

If the rule is finalized, the 6 bulk drug substances will be the first to be included on the 503A bulks list. The FDA’s Pharmacy Compounding Advisory Committee has met 3 times this year to discuss new additions and removals.

“Because of the amount of time that had passed between the publication of the 1999 proposed rule and the enactment of the Drug Quality Security Act, FDA felt it was necessary to begin again to develop the 503A Bulks List,” FDA officials said in a statement.

The FDA will be open to receiving comments on the proposed rule for 90 days.

Related Videos
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.